EC Orthopaedics

Review Article Volume 16 Issue 1 - 2025

Cancer Bone Metastasis, Circulation Biomarker Profiling

Da-Yong Lu*

School of Life Sciences, Shanghai University, Shanghai, China

*Corresponding Author: Da-Yong Lu, School of Life Sciences, Shanghai University, Shanghai, China.
Received: September 17, 2024; Published: November 22, 2024



Cancer bone metastasis was common features for cancer patients. It is very painful for patients and therapeutic resistance in the clinic. Drug treatment needs to improve for both growth inhibition and symptom management. To promote therapeutic paradigms, clinical drug treatment should be personalized by different platforms and paradigms. This editorial discusses bone cancer metastasis treatment in personalized medicine.

 Keywords: Bone Cancer; Neoplasm Metastasis; Drug Treatment; Clinical Trial

  1. Lambert AW., et al. “Emerging biological principles of metastasis”. Cell 4 (2017): 670-691.
  2. Ahmad AS., et al. “Trends in the lifetime risk of developing cancer in Great Britain; Comparison of risk for those born from 1930-1960”. British Journal of Cancer 5 (2015): 943-947.
  3. Mehlen P and Puisieux A. “Metastasis; a question of life or death”. Nature Reviews Cancer 6 (2006): 449-458.
  4. Weidenfeld K and Barkan D. “EMT and stemness in tumor dormancy and outgrowth: Are they intertwined processes?” Frontiers in Oncology 8 (2018): 381.
  5. Lu DY and Xu B. “Bone metastasis treatment, major frontiers”. Acta Scientific Orthopaedics7 (2021): 1-2.
  6. Hakim BAA. “Benign bone tumors, an overview”. Acta Scientific Orthopaedics10 (2021): 1-2.
  7. Lu DY and Xu B. “Bone cancer and metastatic trials, drug treatment”. Acta Scientific Orthopaedics9 (2021): 31-33.
  8. Lu DY., et al. “Cancer metastasis treatments”. Current Drug Therapy1 (2013): 24-29.
  9. Bhadresha KP., et al. “A predictive biomarker panel for bone metastasis, liquid biopsy approach”. Journal of bone oncology 29 (2021): 100374.
  10. Lu DY and Xu B. “Cancer bone metastasis, experimental study”. Acta Scientific Orthopeadics12 (2022): 1-3.
  11. Lu DY., et al. “Anti-metastatic drug development, work out towards new direction”. Medicinal Chemistry7 (2018): 192-196.
  12. Lu DY., et al. “Anticancer drug sensitivity testing, a historical review and future perspectives”. Current Drug Therapy1 (2015): 44-55.
  13. Volm M and Efferth T. “Prediction of cancer drug resistance and implications for personalized medicine”. Frontiers in Oncology 5 (2015): 282.
  14. Lu DY and Lu TR. “Drug sensitivity testing, a unique drug selection strategy”. Advances in Biomarker Sciences and Technology 2 (2020): 59-66.
  15. Montero J., et al. “Drug-induced death signaling strategy rapidly predicts cancer response to chemotherapy”. Cell5 (2015): 977-989.
  16. Popova AA and Levkin PA. “Precision medicine in oncology: In vitro drug sensitivity and resistance test (DSRT) for selection of personalized anticancer therapy”. Advanced Therapeutics 2 (2020): 1900100.
  17. Zhang Y., et al. “Anticancer drug sensitivity assay with quantitative heterogeneity testing using single-cell Raman Spectroscope”. Molecules11 (2018): 2903.
  18. Wang JK., et al. “In vitro anticancer drug sensitivity sensing through single-cell Raman Spectroscopy”. Biosensors8 (2021): 286.
  19. Hammoud MK., et al. “Raman micro-spectroscopy monitors acquired resistance to targeted cancer therapy at the cellular level”. Scientific Reports1 (2018): 15278.
  20. Jelgersma C and Vajkoczy P. “How to target spinal metastasis in experimental research: An overview of currently used experimental mouse model and future prospects”. International Journal of Molecular Sciences 11 (2021): 5420.
  21. Pantano F., et al. “Integrin alpha 5 in human breast cancer is a mediator of bone metastasis and a therapeutic target for the treatment of osteolytic lesions”. Oncogene7 (2021): 1284-1299.
  22. Lu DY and Che JY. “Bone disease treatments, importance of technical supports”. Acta Scientific Orthopaedics4 (2021): 55-57.
  23. Lu DY and Lu TR. “Antimetastatic activities and mechanisms of bisdioxopiperazine compounds”. Anti-Cancer Agent in Medicinal Chemistry7 (2010): 564-570.
  24. Zhu H., et al. “DJ-1 mediates the resistance of cancer cells to dihydroarteminisinin through cancer cells through reactive oxygen species removal”. Free Radical Biology and Medicine 71 (2014): 121-132.
  25. Lu DY., et al. “Development of antimetastatic drugs by targeting tumor sialic acids”. Scientia Pharmaceutica3 (2012): 497-508.
  26. Eslami-S Z., et al. “Functional analysis of circulating tumour cells: the KEY to understand the biology of the metastatic cascade”. British Journal of Cancer 5 (2022): 800-810.
  27. Pantel K and Alix-Panabieres C. “Crucial roles of circulating tumor cells in the metastatic cascade and tumor immune escape: biology and clinical translation”. Journal for Immunotherapy of Cancer12 (2022): e005615.
  28. Lu DY., et al. “Drug sensitivity testing for cancer therapy, key areas”. Reviews on Recent Clinical Trials4 (2022): 291-299.
  29. Agarwal N., et al. “Natural herbs as anticancer drugs”. International Journal of PharmTech Research 3 (2012): 1142-1153.
  30. Lu DY., et al. “Natural drug cancer treatment strategies from herbal medicine to chemical or biological drug”. Studies in Natural Products Chemistry 66 (2020): 91-115.
  31. Lu DY and Lu TR. “Herbal medicine in new era”. Hospice and Palliative Medicine International Journal 4 (2019): 125-130.
  32. Lu DY., et al. “Cancer bioinformatics for update anticancer drug developments and personalized therapeutics”. Reviews on Recent Clinical Trials2 (2017): 101-110.
  33. Lu DY., et al. “Pharmacogenetics of cancer therapy: breakthroughs from beyond?” Future Science OA4 (2015): FSO.80.
  34. Hyman DH., et al. “Implementing genome-driven oncology”. Cell4 (2017): 584-599.
  35. Lu DY., et al. “Individualized cancer chemotherapy integrating drug sensitivity tests, pathological profile analysis and computational coordination-an effective strategy to improve clinical treatment”. Medical Hypotheses1 (2006): 45-51.
  36. Lu DY. “Personalized cancer chemotherapy, an effective way for enhancing outcomes in clinics”. Woodhead Publishing, Elsevier, UK (ISBN. 978-0-08-100346-6) (2014).
  37. Lu DY., et al. “Individualized cancer therapy, future approaches”. Current Pharmacogenomics and Personalized Medicine2 (2018): 156-163.
  38. Lu DY., et al. “Anticancer drug combination, how far we can go through?” Anti-Cancer Agents in Medicinal Chemistry 1 (2017): 21-28.
  39. Lu DY., et al. “Drug combination in clinical cancer treatment”. Reviews on Recent Clinical Trials3 (2017): 202-211.
  40. Barani M., et al. “Recent advances in nanotechnology-based diagnosis and treatments of human osteosarcoma”. Biosensors2 (2021): 55.

Da-Yong Lu. "Cancer Bone Metastasis, Circulation Biomarker Profiling." EC Orthopaedics 16.1 (2025): 01-04.

ECronicon Journal

Our Services

Quick Links

Information

Creative Commons LicenseOpen Access by ECronicon is licensed under a Creative Commons Attribution 4.0 International License
Based on a work at www.ecronicon.net